Orforglipron: A GLP-1 Drug Without a Peptide Chain
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Orforglipron shows why a receptor target and a molecule type are different things. It acts at the GLP-1 receptor but is a non-peptide molecule. In April 2026, FDA approved the tablet product Foundayo for weight management in specified adults, alongside reduced-calorie eating and increased physical activity. The approval relied on two randomized, placebo-controlled trials. Weight reduction was greater with treatment, while gastrointestinal side effects and other warnings remained part of the evaluation. The evidence belongs to the reviewed product and indication. Sharing a receptor target does not make drugs interchangeable, and an approved tablet does not validate unrelated research material.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] FDA (2026): Approval of Foundayo, orforglipron
https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
Official US regulator approval announcement

[2] FDA (2026): Orforglipron multidisciplinary review, NDA 220934
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220934Orig1s000MultidisciplineR.pdf
Official US regulator scientific review

EVIDENCE LIMITATIONS
Orforglipron is included as a non-peptide context topic.
This is not a complete safety-label summary or prescribing advice.
Approval is US- and product-specific, not a claim about every jurisdiction or material.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Orforglipron: A GLP-1 Drug Without a Peptide Chain